Who is sponsoring NCT03180463?

NCT03180463 is sponsored by Sclnow Biotechnology Co., Ltd..

What condition does NCT03180463 study?

NCT03180463 studies Osteonecrosis of Femoral Head.

Is NCT03180463 still recruiting?

NCT03180463 is currently suspended. Last updated 14 May 2025.

Last reviewed 2025-05-14 · How we verify

NCT03180463

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)

Suspended Phase 1, PHASE2 Last updated 14 May 2025

What this trial tests

Phase 1, PHASE2 trial testing Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) in Osteonecrosis of Femoral Head in 30 participants. Suspended.

Timeline

31 December 2025

Primary endpoint
30 June 2026

31 December 2026

Quick facts

Lead sponsor	Sclnow Biotechnology Co., Ltd.
Phase	Phase 1, PHASE2
Status	Suspended
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	31 December 2025
Primary completion	30 June 2026
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) — full drug profile →
core decompression

Conditions studied

Osteonecrosis of Femoral Head — all drugs for Osteonecrosis of Femoral Head →

Sponsor

Sclnow Biotechnology Co., Ltd. — full company profile →

Who can join

Eligibility, any sex, with Osteonecrosis of Femoral Head. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating osteonecrosis of femoral head patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Fresh Umbilical Cord Blood-A Source of Multipotent Stem Cells, Collection, Banking, Cryopreservation, and Ethical Concerns.
Devi S, Bongale AM, Tefera MA, Dixit P, et al · · 2023 · cited 17× · PMID 37763198 · DOI 10.3390/life13091794
Bioengineering strategies targeting angiogenesis: Innovative solutions for osteonecrosis of the femoral head.
Zhu W, Xu Z, Zhou D, Xu J, et al · · 2025 · cited 4× · PMID 39866964 · DOI 10.1177/20417314241310541

Verify or expand the search:

Other trials of Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)

Trials testing the same drug.

NCT03186456 — The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cereb · Phase 1 · suspended
NCT03180450 — The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF) · Phase 1, PHASE2 · suspended

Other Sclnow Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT03186456 — The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cereb · Phase 1 · suspended
NCT06589271 — SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration · Phase 1 · suspended
NCT03378414 — Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia · Phase 2 · not yet recruiting
NCT06503471 — SCLife®-UT hUC-MSCs Advanced Therapy Medicinal Products (hUC-MSCs ATMPs) for Patients With Thin Endometrial Infertility · Phase 1 · suspended
NCT03184935 — Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome · Phase 1, PHASE2 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03180463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sclnow Biotechnology Co., Ltd.
Last refreshed: 14 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03180463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing